Revolutionizing Retrosynthesis with Computational Tools

New tools for computer-aided retrosynthesis help scientists streamline route planning, reducing the financial and environmental costs of drug development.

Written byMerck KGaA and The Scientist
| 2 min read

Share
Conceptual photograph of connecting the dots in a pathway through route planning.

Scientists use retrosynthesis to deconstruct a desired target compound into its building blocks and plan the optimal route for therapeutic synthesis.

©iStock, marcoventuriniautieri

In early stage drug manufacturing research, scientists develop synthetic routes to build active pharmaceutical ingredients (APIs). This can be a painstakingly complex process, with traditional route design methods that rely heavily on human expertise, labor-intensive experiments, and trial-and-error approaches producing suboptimal and costly chemical reaction pathways.1 Computer-assisted retrosynthesis technologies that are supported by artificial intelligence (AI) are revolutionizing route design, enabling safer, more sustainable, and green-by-design APIs.2

What Is Retrosynthesis?

Retrosynthesis or retrosynthetic analysis (RA) is a strategic organic chemistry approach that scientists use to construct target molecules from easy-to-make or readily available precursors.2 Following chemical reaction rules to deconstruct a desired product into reactants, this method helps chemists plan synthesis pathways for natural products, APIs, and other complex molecules.1

Traditionally, deconstruction rules have been dictated by human experts, requiring specialized knowledge of synthetic methodologies. For example, human experts need to know how to break chemical structures into the necessary fragments and add the correct functional groups for a reaction to take place. Synthetic chemists may reiterate this process until a structure cannot be further simplified or until they determine a desired route. This dependence on manual reiteration and expertise results in significant resource waste with respect to time, cost, and materials, which has been a barrier to improving route design.1

A Need for Greener Chemistry

Greener chemistry is critical to developing safe and effective APIs as well as downstream therapeutics. Scientists seek greener-by-design synthetic routes that inherently reduce reaction steps, maximize yield, identify greener pathways, and minimize side products and impurities. Combined with green-by-design strategies, computer-aided retrosynthesis can help researchers address route planning challenges, reducing the need for traditional intensive experimentation and lowering development and production costs

Continue reading below...

Like this story? Sign up for FREE Newsletter updates:

Latest science news storiesTopic-tailored resources and eventsCustomized newsletter content
Subscribe

Computer-Aided Retrosynthesis

Computational, data-driven processes increasingly help scientists determine the most efficient retrosynthetic routes. Instead of experimentally determining synthetic pathways to create APIs, researchers use computer-aided retrosynthesis to virtually construct targets from reactant databases.1 Computational tools that integrate AI and machine learning-based techniques can automate key planning and reiteration steps, further accelerating chemistry research and development, including retrosynthesis.3

The SYNTHIA™ platform depicting a flower chart of retrosynthesis pathways and nodes.

Researchers can use computer-aided retrosynthesis to explore unique and innovative API-building routes.

Merck KGaA, Darmstadt, Germany

SYNTHIA™ from Merck KGaA, Darmstadt, Germany is a software platform that employs a hybrid computational retrosynthesis approach, integrating chemist-encoded rules with machine learning algorithms engineered by computer scientists. With a catalog of over 12 million commercially available starting materials and building blocks, SYNTHIA™ allows scientists to quickly discover novel pathways for new and published target molecules. It offers an unbiased, objective, computer-aided approach to simplifying robust synthesis pathway discovery. Researchers can quickly and efficiently scan hundreds of pathways to better identify the best option according to their specific needs.

SYNTHIA™ also provides pathways that utilize enzymes to achieve more sustainable chemical transformations. Its database offers information on reaction conditions, enzyme details, and reference links. Importantly, this supports biocatalysis, a key component of green chemistry. Additionally, SYNTHIA™ incorporates building block sustainability information with clear in-pathway labels, helping researchers design greener synthesis routes.

From experienced synthetic chemists to budding drug design researchers, pairing computer-aided retrosynthesis and green chemistry helps scientists streamline route planning, expediting API development and reducing financial and environmental manufacturing costs.

Merck KGaA, Darmstadt, Germany



Illustration of a developing fetus surrounded by a clear fluid with a subtle yellow tinge, representing amniotic fluid.
January 2026

What Is the Amniotic Fluid Composed of?

The liquid world of fetal development provides a rich source of nutrition and protection tailored to meet the needs of the growing fetus.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies

Parse Logo

Parse Biosciences and Graph Therapeutics Partner to Build Large Functional Immune Perturbation Atlas